Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aurinia Pharm Ord
(NQ:
AUPH
)
4.870
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
Next >
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
December 09, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
November 03, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
November 01, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
October 27, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
October 26, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
September 15, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals finalizes acquisition agreement with Leading Pharma Giant
August 26, 2021
Via
Get News
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
August 17, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
August 09, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 05, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
July 26, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
July 16, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
June 30, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
June 25, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
June 14, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Results of the 2021 Annual General Meeting
June 07, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
June 07, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
May 20, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 14, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
May 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
May 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
May 06, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
April 28, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 15, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
April 08, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.